NCT01912768

Brief Summary

The purpose of this study is demonstrate substantial equivalence of an investigational contact lens disinfecting solution to a commercially available contact lens solution in silicone hydrogel and soft contact lens wearers.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
362

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2013

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 29, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 31, 2013

Completed
4 months until next milestone

Study Start

First participant enrolled

December 1, 2013

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2014

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

June 9, 2015

Completed
Last Updated

July 9, 2015

Status Verified

June 1, 2015

Enrollment Period

5 months

First QC Date

July 29, 2013

Results QC Date

May 26, 2015

Last Update Submit

June 10, 2015

Conditions

Keywords

contact lensescontact lens solutionsoft contact lenses

Outcome Measures

Primary Outcomes (12)

  • Percentage of Subjects With Visibly Clean Lenses

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered. A lens was considered visibly clean if it had nondetectable films or deposits. One eye (study eye) contributed to the analysis.

    Day 7, Day 30, Day 60, Day 90

  • Percentage of Subjects With Crystalline Deposits by Type

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered: Type II = films or deposits visible only under special conditions, such as special illumination using an eyepiece of 7-10 times magnification, Type III = films or deposits readily visible on a dry lens under room lighting, with unaided eye, and Type IV = films or deposits obvious under room lighting, with unaided eye, when the lens is wet or dry. One eye (study eye) contributed to the analysis.

    Day 7, Day 30, Day 60, Day 90

  • Percentage of Subjects With Film Deposits by Type

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered: Type II = films or deposits visible only under special conditions, such as special illumination using an eyepiece of 7-10 times magnification, Type III = films or deposits readily visible on a dry lens under room lighting, with unaided eye, and Type IV = films or deposits obvious under room lighting, with unaided eye, when the lens is wet or dry. One eye (study eye) contributed to the analysis.

    Day 7, Day 30, Day 60, Day 90

  • Average Residual Lens Lysozyme

    Worn study lenses were removed and analyzed by high performance liquid chromatography (HPLC) for residual lens lysozyme (protein). Values reported as lower than the limit of quantitation or none detected were imputed as 0.5 μg or 0 μg, respectively. A lower value indicates less lysozyme deposition. One eye (study eye) contributed to the analysis.

    Day 30/Early Exit

  • Percentage of Subjects With Change From Baseline in Contact Lens-Corrected Distance Visual Acuity (CLCDVA) by Line Change

    Distance VA was assessed for each eye individually while reading a chart distant to the participant in dimmed room illumination. VA was measured using a Snellen chart, with 20/20 Snellen acuity considered normal distance-eyesight. A line increase indicates an improvement in VA. One eye (study eye) contributed to the analysis.

    Baseline (Day 0), Day 7, Day 30, Day 60, Day 90

  • Average Lens Wear Time

    Subject recorded a response to the question, "Averaging over the last 3 days, how many hours per day did you wear your contact lenses?" Lens wear time was measured in hours.

    Day 7, Day 30, Day 60, Day 90

  • Number of Unscheduled Lens Replacements by Reason

    A fresh pair of lenses was dispensed on Day 0, Day 30, and Day 60. Lenses replaced at other times were considered unscheduled. The counts in the table represent the total number of unscheduled lenses replaced by reason for any eye, any subject.

    Up to Day 90

  • Likert Item - "When I Use This Solution, my Lenses Are Comfortable All Day."

    Lens comfort was assessed by the subject as a single response on a 5-point Likert scale (Strongly Agree, Agree, Undecided, Disagree, Strongly Disagree) to best describe their lens wearing experience over the last 3 days. Responses were summarized by agreement category and presented as percentage of subjects.

    Day 7, Day 30, Day 60, Day 90

  • Likert Item - "When I Use This Solution, at the End of the Lens Wearing Day my Vision is Clear."

    Clear vision was assessed by the subject as a single response on a 5-point Likert scale (Strongly Agree, Agree, Undecided, Disagree, Strongly Disagree) to best describe their lens wearing experience over the last 3 days. Responses were summarized by agreement category and presented as percentage of subjects.

    Day 7, Day 30, Day 60, Day 90

  • Likert Item - "When I Use This Solution, I Like the Way This Product Feels During Handling."

    Product handling was assessed by the subject as a single response on a 5-point Likert scale (Strongly Agree, Agree, Undecided, Disagree, Strongly Disagree) to best describe their lens wearing experience over the last 3 days. Responses were summarized by agreement category and presented as percentage of subjects.

    Day 7, Day 30, Day 60, Day 90

  • Crystalline Deposit Area Covered

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered. Values were reported as a percentage of lens area covered. One eye (study eye) contributed to the analysis.

    Day 7, Day 30, Day 60, Day 90

  • Film Deposit Area Covered

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered. Values were reported as a percentage of lens area covered. One eye (study eye) contributed to the analysis.

    Day 7, Day 30, Day 60, Day 90

Study Arms (2)

FID 120947A

EXPERIMENTAL

FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 90 days

Device: FID 120947A contact lens disinfecting solutionDevice: Soft contact lenses

renu fresh

ACTIVE COMPARATOR

Renu fresh multi-purpose solution used with soft contact lenses (study lenses) on a daily basis for 90 days

Device: renu fresh multi-purpose solutionDevice: Soft contact lenses

Interventions

Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses

Also known as: Clear Care® Plus
FID 120947A

Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses

renu fresh

Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.

FID 120947Arenu fresh

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Normal eyes (other than correction for visual acuity);
  • Successful history of silicone hydrogel or soft contact lens wear in both eyes in one of the following brands: Soflens® 38, Proclear DW, Frequency 55, Acuvue® Oasys™, Air Optix Aqua, O2 OPTIX, Air Optix for Astigmatism, Air Optix Aqua Multifocal, Biofinity®, PureVision®, PureVision®2;
  • Best spectacle corrected distance visual acuity greater than or equal to 20/25 in each eye;

You may not qualify if:

  • Any ocular or systemic medical condition that may, in the opinion of the investigator, preclude safe administration of the investigational products or affect the results of this study;
  • Need to wear contact lenses on an extended wear basis (ie, overnight) during the study;
  • Use of a daily cleaner and/or an enzyme cleaner to care for lenses at least 7 days prior to Visit 1;
  • History of intolerance or hypersensitivity to any component of the investigational products;
  • Use of all over-the-counter (OTC) or prescribed topical ocular medications within 7 days prior to Visit 1;
  • Moderate, severe, abnormal, or other ocular findings;
  • Current or history of ocular infection, severe inflammation, or disease within 6 months prior to Visit 1;
  • Any systemic disease at Visit 1 (including allergies, respiratory infections or colds) that may affect the eye or be exacerbated by use of contact lenses or contact lens solutions;
  • Use of systemic medications that may contribute to adverse ocular effects unless on a stable dosing regimen;
  • Ocular surgery within the last 12 months;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

MyopiaAstigmatismHyperopiaRefractive Errors

Interventions

Contact Lenses, Hydrophilic

Condition Hierarchy (Ancestors)

Eye Diseases

Intervention Hierarchy (Ancestors)

Contact LensesLensesOptical DevicesEquipment and Supplies

Results Point of Contact

Title
Clinical Project Lead, GCRA
Organization
Alcon Research, Ltd.

Study Officials

  • Monica Studzinski, Lead CSM

    Alcon Research

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 29, 2013

First Posted

July 31, 2013

Study Start

December 1, 2013

Primary Completion

May 1, 2014

Study Completion

May 1, 2014

Last Updated

July 9, 2015

Results First Posted

June 9, 2015

Record last verified: 2015-06